Patents Assigned to Valneva
  • MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO
    Publication number: 20230322869
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Application
    Filed: January 6, 2023
    Publication date: October 12, 2023
    Applicant: Valneva Austria GmbH
    Inventors: URBAN LUNDBERG, Wolfgang Schüler
  • METHOD OF PRODUCING PHARMACEUTICAL COMPOSITIONS COMPRISING IMMUNOGENIC CHIKUNGUNYA VIRUS CHIKV-DELTA5NP3
    Publication number: 20230293661
    Abstract: The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.
    Type: Application
    Filed: September 26, 2022
    Publication date: September 21, 2023
    Applicant: Valneva SE
    Inventors: Andrea Fritzer, Andreas Meinke, Urban Lundberg, Mario Nebenfuhr, Jurgen Heindl-Wruss, Robert Schlegl, Arnaud Leon
  • MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO
    Publication number: 20230295245
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Application
    Filed: September 14, 2022
    Publication date: September 21, 2023
    Applicant: Valneva Austria GmbH
    Inventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
  • ZIKA VIRUS VACCINE
    Publication number: 20230226165
    Abstract: Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Application
    Filed: March 6, 2023
    Publication date: July 20, 2023
    Applicant: Valneva Austria GmbH
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
  • CpG-adjuvanted SARS-CoV-2 virus vaccine
    Patent number: 11684669
    Abstract: Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: June 27, 2023
    Assignees: Valneva Austria GmbH, Dynavax Technologies Corporation
    Inventors: Andreas Meinke, Michael Möhlen, Christoph Reinisch, Robert Schlegl, Christian Taucher, John Campbell, David Novack, Robert S. Janssen, Jürgen Heindl-Wruss
  • COMPOSITIONS COMPRISING THREE OSPA FUSION PROTEINS FOR MEDICAL USE
    Publication number: 20230173051
    Abstract: The present invention relates to a composition comprising the OspA fusion protein of SEQ ID NO: 1 (LipSID1-S2D1), the OspA fusion protein of SEQ ID NO: 2 (Lip-S4D1-SShybD1) and the OspA fusion protein of SEQ ID NO: 3 (Lip-S5D1-S6D1) for use in a vaccine or for use in a method for eliciting an immune response in a human against Lyme disease.
    Type: Application
    Filed: April 9, 2021
    Publication date: June 8, 2023
    Applicants: Valneva Austria GmbH, Pfizer Inc.
    Inventors: Nicole Bézay, Romana Hochreiter, Urban Lundberb, Steven Russell Bailey, Annaliesa Sybil Anderson, Kathrin Ute Jansen, Daniel Alfred Scott
  • ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF
    Publication number: 20230173052
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Application
    Filed: September 9, 2022
    Publication date: June 8, 2023
    Applicants: VALNEVA AUSTRIA GMBH, VALNEVA USA, INC.
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • MULTIVALENT OSPA POLYPEPTIDES AND METHODS AND USES RELATING THERETO
    Publication number: 20230151063
    Abstract: The present invention relates to an immunogenic polypeptide, a nucleic acid encoding the same, a pharmaceutical composition comprising the same and the immunogenic polypeptide, nucleic acid or pharmaceutical composition for use as a medicament, particularly a vaccine, or for use in a method of treating or preventing a Borrelia infection.
    Type: Application
    Filed: April 13, 2018
    Publication date: May 18, 2023
    Applicant: Valneva Austria GmbH
    Inventors: Urban Lundberg, Andreas Meinke, Abhijeet Nayak, Wolfgang Schüler
  • Aseptic purification process for viruses
    Patent number: 11629339
    Abstract: Described herein are processes for the purification of viruses and compositions thereof.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: April 18, 2023
    Assignee: Valneva SE
    Inventors: Robert Schlegl, Michael Weber
  • CORONAVIRUS VACCINES COMPRISING A TLR9 AGONIST
    Publication number: 20230092650
    Abstract: The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guano sine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against a SARS-CoV-2 in an individual in need thereof.
    Type: Application
    Filed: March 1, 2021
    Publication date: March 23, 2023
    Applicants: Dynavax Technologies Corporation, Valneva Austria GmbH
    Inventors: John D. Campbell, Robert S. Janssen, David Novack, Christian Taucher, Christoph Reinisch, Andreas Meinke, Michael Möhlen, Robert Schlegl, Jürgen Heindl-Wruss
  • VIRUS PURIFICATION
    Publication number: 20230056142
    Abstract: Described herein are processes for purifying infectious virus particles and uses of protamine in such processes.
    Type: Application
    Filed: July 6, 2022
    Publication date: February 23, 2023
    Applicant: VALNEVA SE
    Inventors: Jana BARBERO CALZADO, Mario NEBENFÜHR, Robert SCHLEGL, Michael WEBER, Jürgen HEINDL-WRUSS
  • CpG-ADJUVANTED SARS-CoV-2 VIRUS VACCINE
    Publication number: 20230038284
    Abstract: Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Application
    Filed: September 10, 2021
    Publication date: February 9, 2023
    Applicants: Valneva Austria GmbH, Dynavax Technologies Corporation
    Inventors: Andreas Meinke, Michael Möhlen, Christoph Reinisch, Robert Schlegl, Christian Taucher, John Campbell, David Novack, Robert S. Janssen
  • Mutant fragments of OspA and methods and uses relating thereto
    Patent number: 11572392
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: February 7, 2023
    Assignee: Valneva Austria GmbH
    Inventors: Urban Lundberg, Wolfgang Schüler
  • Zika virus purification
    Patent number: 11524064
    Abstract: Described herein are processes for purifying infectious Zika virus particles and uses of protamine in such processes.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: December 13, 2022
    Assignee: Valneva Austria GmbH
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schiegl, Michael Weber, Jürgen Heindl-Wruss
  • Method of producing pharmaceutical compositions comprising immunogenic Chikungunya virus CHIKV-Delta5nsP3
    Patent number: 11484587
    Abstract: The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: November 1, 2022
    Assignee: Valneva SE
    Inventors: Andrea Fritzer, Andreas Meinke, Urban Lunberg, Mario Nebenfuhr, Jurgen Heindl-Wruss, Robert Schlegl, Arnaud Leon
  • Isolated polypeptide of the toxin A and toxin B proteins of and uses thereof
    Patent number: 11478540
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: October 25, 2022
    Assignees: Valneva Austria GmbH, Valneva USA, Inc.
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • Mutant fragments of OspA and methods and uses relating thereto
    Patent number: 11466058
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: October 11, 2022
    Assignee: Valneva Austria GmbH
    Inventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
  • SINGLE SHOT CHIKUNGUNYA VIRUS VACCINE
    Publication number: 20220313810
    Abstract: The present invention relates to a single-shot live attenuated vaccine against Chikungunya virus which is well-tolerated and induces long-lasting protective immunity in adult human subjects.
    Type: Application
    Filed: August 10, 2020
    Publication date: October 6, 2022
    Applicant: Valneva SE
    Inventors: Nina Wressnigg, Romana Hochreiter
  • INACTIVATION PROCESS FOR VIRUSES
    Publication number: 20220298493
    Abstract: Described herein are methods for inactivation of viruses with high yield and recovery, and compositions produced by such methods.
    Type: Application
    Filed: March 8, 2022
    Publication date: September 22, 2022
    Applicant: Valneva Austria GmbH
    Inventors: Robert Schlegl, Jürgen Heindl-Wruss
  • CHIKUNGUNYA VACCINE FORMULATIONS
    Publication number: 20220288185
    Abstract: The present invention is related to novel liquid and lyophilized formulations of Chikungunya virus useful as vaccines and methods for their preparation.
    Type: Application
    Filed: August 10, 2020
    Publication date: September 15, 2022
    Applicant: Valneva SE
    Inventors: Christoph Reinisch, Robert Schlegl, Jürgen Heindl-Wruss